Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary (2011)
Chapter: Acronyms
|
AACI |
Association of American Cancer Institutes |
|
ACOSOG |
American College of Surgeons Oncology Group |
|
ACRIN |
American College of Radiology Imaging Network |
|
ALL |
acute lymphoblastic leukemia |
|
AMA |
American Medical Association |
|
AML |
acute myeloid leukemia |
|
ASCO |
American Society of Clinical Oncology |
|
ASO |
administrative services only |
|
BIQSFP |
Biomarker, Imaging, and Quality of Life Studies Funding Program |
|
BUN |
blood urea nitrogen concentration |
|
caBIG |
Cancer Biomedical Informatics Grid |
|
CALGB |
Cancer and Leukemia Group B |
|
CAM |
complementary and alternative medicine |
|
CBER |
Center for Biologics Evaluation and Research |
|
CCOP |
Community Clinical Oncology Program |
|
CCSG |
Cancer Center Support Grant |
|
CDER |
Center for Drug Evaluation and Research |
|
CDRH |
Center for Devices and Radiological Health |
|
CEBP |
CCAAT/Enhancer Binding Protein |
|
CED |
coverage with evidence development |
|
CIRB |
Central Institutional Review Board |
|
CLIA |
Clinical Laboratory Improvement Amendments |
|
CME |
continuing medical education |
|
CMS |
Centers for Medicare and Medicaid Services |
|
COG |
Children’s Oncology Group |
|
CPC |
Cancer Prevention and Control |
|
CPT |
Common Procedural Terminology |
|
CRADA |
Cooperative Research and Development Agreement |
|
CRF |
case report form |
|
CT |
computed tomography |
|
CTAC |
Clinical and Translational Research Advisory Committee |
|
CTEP |
Cancer Therapy Evaluation Program |
|
CTSU |
Cancer Trials Support Unit |
|
CTWG |
Clinical Trials Working Group |
|
DCTD |
Division of Cancer Treatment and Diagnosis |
|
ECOG |
Eastern Cooperative Oncology Group |
|
EMA |
European Medicines Agency |
|
ERISA |
Employee Retirement Income Security Act |
|
FDA |
Food and Drug Administration |
|
FLT3/ITD |
fms-like tyrosine kinase receptor-3/internal tandem duplication |
|
FOA |
Funding Opportunity Announcement |
|
GOG |
Gynecological Oncology Group |
|
HCPCS |
Healthcare Common Procedure Coding System |
|
HER2 |
human epidermal growth factor receptor 2 |
|
HHS |
U.S. Department of Health and Human Services |
|
IDE |
investigational device exemption |
|
IND |
investigational new drug |
|
IOM |
Institute of Medicine |
|
IP |
intellectual property |
|
IRB |
Institutional Review Board |
|
IT |
information technology |
|
KRAS |
Kirsten ras oncogene |
|
MTA |
Material Transfer Agreement |
|
NCCN |
National Cooperative Cancer Network |
|
NCCTG |
North Central Cancer Treatment Group |
|
NCI |
National Cancer Institute |
|
NDA |
new drug applications |
|
NHBLI |
National Heart, Lung, and Blood Institute |
|
NIH |
National Institutes of Health |
|
NLM |
National Library of Medicine |
|
NSABP |
National Surgical Adjuvant Breast and Bowel Project |
|
OEWG |
Operational Efficiency Working Group |
|
OHRP |
Office for Human Research Protections |
|
OPEN |
Oncology Patient Enrollment Network |
|
OSU |
Ohio State University |
|
PET-CT |
positron emission tomography-computed tomography |
|
PhRMA |
Pharmaceutical Research and Manufacturers of America |
|
PI |
principal investigator |
|
RECIST |
Response Evaluation Criteria in Solid Tumors |
|
RFA |
Request for Applications |
|
RTOG |
Radiation Therapy Oncology Group |
|
RUC |
Relative Value Scale Update Committee |
|
SACHRP |
Secretary’s Advisory Committee on Human Research Protections |
|
SJO |
St. Joseph Hospital, Orange, California |
|
sNDA |
supplemental new drug application |
|
SPA |
Special Protocol Assessment |
|
SPORE |
Specialized Program of Research Excellence |
|
START |
Standard Terms of Agreement for Research Trials |
|
SWOG |
Southwest Oncology Group |
|
TAILORx |
Trial Assigning IndividuaLized Options for Treatment |
|
TARGET |
Therapeutically Applicable Research to Generate Effective Treatments |
